← All Instil Bio, INC filings

Instil Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TIL
Instil Bio, INC
10-K: Instil Bio Shifts Strategy After AXN-2510 Discontinuation
Instil Bio, a biotechnology company, has discontinued its lead product candidate AXN-2510 and is now actively seeking to acquire new therapeutic candidates, facing ongoing significant losses and a going concern indicator.
NASDAQ
TIL
Instil Bio, INC
10-K: Instil Bio Reports FY2024 Results, Focuses on Bispecific Antibody Development
Instil Bio shifts focus to bispecific antibody AXN-2510/IMM2510, reports \$74.1 million net loss for FY2024, and anticipates funding operations beyond 2026.
NASDAQ
TIL
Instil Bio, INC
10-K: Instil Bio Announces Strategic Shift, Halts Clinical Trials, Focuses on Collaboration
Instil Bio is closing its UK manufacturing and clinical trial operations, ceasing all ITIL-306 Phase 1 clinical trial activities, and focusing on a collaboration in China for a new autologous FR CoStAR-TIL product.